MedTrace Logo

A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis

NCT02778399 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 328

Last updated 2022-07-21

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to assess the efficacy and safety of a range of oral doses of OBE2109 versus placebo, in reducing endometriosis associated pain.

Conditions

  • Endometriosis

Interventions

DRUG

Placebo

Placebo tablets for oral administration once daily

DRUG

OBE2109

OBE2109 tablets for oral administration once daily

Sponsors & Collaborators

  • ObsEva SA

    lead INDUSTRY

Principal Investigators

  • ObsEva SA · Geneva

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2018-04-30
Completion
2019-07-01

Countries

  • United States
  • Poland
  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02778399 on ClinicalTrials.gov